Priming effect with G-CSF enhances in vitro apoptosis by treatment with Ara-c and VP-16 in leukemic cell line

被引：0
|
作者：
Kitagawa, Jun-Ichi [1 ]
Hara, Takeshi [1 ]
Tsurumi, Hisashi [1 ]
Kanemura, Nobuhiro [1 ]
Shimizu, Masahito [1 ]
Moriwai, Hisataka [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Dept Internal Med 1, Gifu, Japan
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4333.4333
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4333
引用
收藏
页码：151B / 151B
页数：1
相关论文
共 50 条
  • [31] PREDICTABILITY AND COSTS ASSOCIATED WITH GOOD AND POOR MOBILIZERS USING A COMBINATION OF VP-16 AND G-CSF FOR PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION AND COLLECTION
    Wood, W. A.
    Whitley, J. S.
    Moore, D. T.
    Sharf, A.
    Irons, R.
    Rao, K., V
    Serody, J. S.
    Gabriel, D. A.
    Coghill, J. M.
    Shea, T. C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S236 - S236
  • [32] Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers
    S Giebel
    T Kruzel
    T Czerw
    M Sadus-Wojciechowska
    J Najda
    E Chmielowska
    S Grosicki
    A Jurczyszyn
    M Pasiarski
    E Nowara
    M Glowala-Kosinka
    A Chwieduk
    I Mitrus
    A Smagur
    J Holowiecki
    Bone Marrow Transplantation, 2013, 48 : 915 - 921
  • [33] Evaluating the clinical efficiacy of etoposide (VP-16) +G-CSF 10 mcg/kg for peripheral blood progenitor cell mobilisation in patients with acute myeloid leukaemia
    Pivkova, A
    Cevreska, L
    Siljanovski, N
    Stojanoski, Z
    Stavrik, SG
    Panovska, L
    Balkanov, SK
    Trajkova, S
    Georgievski, B
    BONE MARROW TRANSPLANTATION, 2006, 37 : S124 - S125
  • [34] Phase II study of Idarubicine, Fludarabine, ARA-C, and G-CSF (IDA-Flag) for treatment of refractory, relapsed or secondary acute myeloid leukemia
    Steinmetz, HT
    Staib, P
    Glasmacher, A
    Neufang, A
    Katay, I
    Diehl, V
    Wickramanayake, PD
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 821 - 821
  • [35] Autologous peripheral blood stem cell transplant using busulfan, etoposide, high dose Ara-C, and G-CSF priming as conditioning regimen in patients with acute myeloid leukemia in first complete remission
    Moscardo, F.
    Diaz Mediavilla, J.
    de la Rubia, J.
    Fernandez, P.
    Rayon, C.
    Canigral, G.
    Arias, J.
    Palomera, L.
    Bello, J. L.
    Alcala, A.
    Sayas, M. J.
    Burgaleta, C.
    Mateos, M.
    Amador, L.
    Perez, M.
    Fernandez, R.
    Garcia, J.
    Martin, M. V.
    Roman, A.
    Queizan, J. A.
    Fernandez, J.
    Sanz, M. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 9 - 9
  • [36] THE EFFICACY AND SAFETY OF VP-16 AND G-CSF AS A MOBILIZATION REGIMEN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) AND LYMPHOMA
    Whitley, J. S.
    Wood, W. A.
    Moore, D. T.
    Sharf, A.
    Irons, R.
    Rao, K., V
    Serody, J. S.
    Gabriel, D. A.
    Coghill, J. M.
    Shea, T. C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S235 - S235
  • [37] TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) - THE INCORPORATION OF DIVIDED DOSE ORAL METHOTREXATE (DMTX) L-ASPARAGINASE (L-ASP) AND VP-16/ARA-C
    WINICK, N
    BOWMAN, WP
    BUCHANAN, GR
    SARTAIN, P
    KAMEN, B
    CLINICAL RESEARCH, 1990, 38 (01): : A61 - A61
  • [38] TREATMENT OF REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND CHRONIC MYELOGENOUS LEUKEMIA IN BLASTIC PHASE (CML-BP) WITH VP-16, INTERMEDIATE-DOSE ARA-C AND CARBOPLATIN
    AMADORI, S
    FAZI, P
    PETTI, MC
    PICARDI, A
    CARUSO, R
    MANDELLI, F
    BLOOD, 1993, 82 (10) : A131 - A131
  • [39] DOSAGE ADJUSTMENT TO ACHIEVE TARGET PLASMA-CONCENTRATIONS OF CONTINUOUS INFUSION CYTARABINE (ARA-C) AND ETOPOSIDE (VP-16) IN THE TREATMENT OF ACUTE NON-LYMPHOCYTIC LEUKEMIA (ANLL)
    CROM, WR
    MIRRO, J
    BAKER, DK
    PETROS, WP
    BELT, JK
    PHARMACOTHERAPY, 1988, 8 (02): : 137 - 137
  • [40] Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML.
    Ossenkoppele, G
    Graveland, W
    Sonneveld, P
    Daenen, S
    Biesma, D
    Verdonck, L
    Schaafsma, M
    Westveer, P
    Peters, G
    Noordhuis, P
    Muus, P
    Selleslag, D
    van der Holt, B
    Delforge, M
    Lowenberg, B
    Verhoef, G
    BLOOD, 2002, 100 (11) : 792A - 793A
12345